For Now, Competitive Generic Therapy Exclusivity Is A Mirage

By Sinchan Shah, Jaimin Shah and Stephen Auten (February 12, 2019, 3:11 PM EST) -- Exorbitantly high prices are not just a problem for patented drugs. Even off-patent drugs are subject to high prices when there is inadequate generic competition due to market size or regulatory barriers. For example, the toxoplasmosis drug Daraprim, which has a small market (approximately, $10 million in 2015-16). Turing Pharmaceuticals acquired the product and immediately raised the price from $13.50 to $750 a pill.[1] The tuberculosis drug cycloserine is another example, where the price for 30 pills was raised from $500 to $10,800.[2]...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!